Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial

Avenge Bio CEO and Key Executive Team

avengebio (@AvengeBio) / X

Avenge Bio to Begin Clinical trials of Immunotherapy Technology, Department of Bioengineering

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk

Biotech, Pharmaceutical and Clinical Research News

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

avengebio (@AvengeBio) / X

Games Workshop - Rogue Trooper - Avenge the Quartz Zone Massacre Board Game

Mike Tyson named his knockout of Larry Holmes as his GOAT knockout because he got to avenge Muhammad Ali 🔥 LINK IN BIO FOR FULL EPISODE OF …

Bio Tech Nutra Avenger - Stack3d Database